Immune Design

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Immune Design and buy or sell other stocks, ETFs, and their options commission-free!

About IMDZ

Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. 

CEO
Rita A. Karachun
CEORita A. Karachun
Employees
Employees
Headquarters
Kenilworth, New Jersey
HeadquartersKenilworth, New Jersey
Founded
2008
Founded2008
Employees
Employees

IMDZ Key Statistics

Market cap
282.03M
Market cap282.03M
Price-Earnings ratio
-5.14
Price-Earnings ratio-5.14
Dividend yield
Dividend yield
Average volume
178.76K
Average volume178.76K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$5.85
52 Week high$5.85
52 Week low
$1.10
52 Week low$1.10

Stock Snapshot

With a market cap of 282.03M, Immune Design(IMDZ) trades at $5.85. The stock has a price-to-earnings ratio of -5.14.

Immune Design(IMDZ) stock opened on 2026-03-06 at —. The price climbed to — and dipped to —.

Immune Design(IMDZ) shares are trading with a volume of 0, against a daily average of 178.76K.

In the last year, Immune Design(IMDZ) shares hit a 52-week high of $5.85 and a 52-week low of $1.10.

In the last year, Immune Design(IMDZ) shares hit a 52-week high of $5.85 and a 52-week low of $1.10.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.